Abstract:OBJECTIVE:Monoclonal antibody (mAb) conjugated with certain toxin to generate immunotoxin bears an important and promising effect as a new therapy for patients with hematopoietic malignancies. However, most toxic moieties conjugated with antibody proteins reported in the literature were toxic proteins which presented immunogenicity to patients capable of inducing anti-toxin antibody. Norcantharidin (NCTD) is a small molecule toxin. It does not have the immunogenicity to human body so that it bears a promising potential for development of new targeting drug. In this study, a new clone of self-made anti-CD19 mAb named ZCH-4-2E8 conjugated with NCTD was used to investigate its targeting efficacy against CD19+ lymphoid malignant Nalm-6 cells in vitro to provide the experimental data for the further development of this new targeting agent.METHODS:A monoclonal antibody named 2E8 was prepared from mouse ascites and purified by gel chromatography. The purity of the antibody protein was checked by SDS-PAGE assay. Immunotoxin 2E8-NCTD was successfully generated through conjugating CD19 mAb protein and Norcantharidin by the activated ester method. The binding activity of the immunoconjugate (2E8-NCTD) against CD19 antigens on cell surface and the expression levels of CD19 antigens on Nalm-6 and K562 cells were examined by flow cytometry. Comparisons of the inhibitory effects among PBS, purified 2E8 antibody, norcantharidin and immunotoxin 2E8-NCTD groups on cell growth of either Nalm-6 cells or K562 cells were made.RESULTS:The purity of the purified 2E8 antibody was higher than 99.00% demonstrated by SDS-PAGE assay. 2E8 antibody in the supernatant reacted with 99.34% of Nalm-6 cells, while only 0.98% of K562 cells reacted with this antibody. The newly generated immunotoxin (2E8-NCTD) had a positive rate of 99.90% on Nalm-6 cells with little reduction of binding activity. From the in vitro study, both 2E8-NCTD and norcantharidin were shown to have significant inhibitory effects on the growth of CD19+ Nalm-6 cells (P < 0.001), while the purified 2E8 antibody did not show any significant influences on the growth of Nalm-6 cells. Since no significant inhibitory effects were identified among immunotoxin 2E8-NCTD, 2E8 antibody and control groups on CD19(-) K562 cells, a significant targeting effect of the 2E8-NCTD against Nalm-6 cells was confirmed.CONCLUSIONS:The immunotoxin 2E8-NCTD was successfully synthesized by activated ester method with an excellent targeting killing effect on CD19+ Nalm-6 leukemia cells in vitro, which provides some experimental data for the further development of this new targeting agent.

Targeted Anti-Tumor Agents and Their Cytotoxicity on Gastric Cancer Cells in Vitro.

Cytotoxicity of Indirect Immunotoxin Mediated by Anti-Gastric Cancer Monoclonal Antibodies on Tumor Cells

Anti-Cancer Activity of Anti-P185her-2 Ricin A Chain Immunotoxin on Gastric Cancer Cells

Preparation of Antigastric Cancer Monoclonal Antibody-Mitomycin-C Conjugate Via A New Type of Conjugation Method

Effect of Targeting Treatment of Mitomycin-C Immunoconjugate on Stomach Neoplasm

Preclinical Evaluation Of Anti-Ron Antibody-Drug Maytansinoid Conjugates (Anti-Ron Adc) For Targeted Colorectal Cacner Therapy.

THE SPECIFIC PHOTODYNAMIC EFFECTS OF MONOCLONAL ANTIBODIES CONJUGATED WITH HEMATOPORPHYRIN DERIVATIVE ON GASTRIC CANCER IN VITRO AND IN VIVO

Study on the Preparation of the Immunotoxin 2E8-NCTD and Its Targeting Killing Effect in Vitro.

Human Cytotoxic T-lymphocyte Membrane-Camouflaged Nanoparticles Combined with Low-Dose Irradiation: a New Approach to Enhance Drug Targeting in Gastric Cancer

Combined Effect of 5-Fluorouracil and Recombinant Tumor Necrosis Factor Against Human Gastric Carcinoma Cell Lines.

Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects

A Novel 5T4-Targeting Antibody-Drug Conjugate H6-DM4 Exhibits Potent Therapeutic Efficacy in Gastrointestinal Tumor Xenograft Models.

[Bispecific McAb Mediated Multiple Tumor Cytotoxicity in Gastric Cancer].

Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C.

[Development of Therapeutic Antibodies for Gastric and Colorectal Cancers].

Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts

Intracellular Delivery of Mitomycin C with Targeted Polysaccharide Conjugates Against Multidrug Resistance

[Conjugation of Mitoxantrone-Loaded Nanospheres and Anti-C-erbb-2 Monoclonal Antibodies].

Monoclonal Antibodies Against Human Gastric Cancer

Preperation and Identification of HER2-targeting Monoclonal Antibodies Suppressing Gastric Carcinoma Cells

IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells